Subtopic Deep Dive
Pulmonary Fibrosis in Systemic Sclerosis
Research Guide
What is Pulmonary Fibrosis in Systemic Sclerosis?
Pulmonary fibrosis in systemic sclerosis (SSc) is interstitial lung disease characterized by excessive extracellular matrix deposition in the lungs of SSc patients, representing the leading cause of mortality.
SSc-associated pulmonary fibrosis manifests as progressive interstitial lung disease with high-resolution CT patterns correlating to histopathological findings (Štorkánová et al., 2021, 4991 citations). Nintedanib reduces forced vital capacity decline in these patients (Distler et al., 2019, 1497 citations). Classification criteria identify early SSc with lung involvement (van den Hoogen et al., 2013, 3271 citations).
Why It Matters
Pulmonary complications account for over 50% of SSc deaths, shifting from renal crises since 1972 (Steen & Medsger, 2007, 1489 citations). Antifibrotic nintedanib slows FVC decline by 44% in SSc-ILD, extending trial-free survival (Distler et al., 2019, 1497 citations). Plasma Hsp90 biomarkers correlate with lung fibrosis progression, enabling risk stratification (Štorkánová et al., 2021, 4991 citations). TGF-β drives fibrotic signaling shared across SSc and pulmonary fibrosis (Frangogiannis, 2020, 1135 citations).
Key Research Challenges
Heterogeneous Fibrotic Pathways
SSc fibrosis involves unique autoimmunity-vasculopathy sequences preceding lung matrix deposition, differing from idiopathic pulmonary fibrosis (Varga & Abraham, 2007, 1127 citations). Common TGF-β mechanisms overlap with other fibroproliferative diseases but require SSc-specific targeting (Wynn, 2007, 1433 citations). Distinguishing shared versus unique regulators remains unresolved.
Predicting Lung Progression
Plasma biomarkers like Hsp90 associate with FVC decline and CT fibrosis scores, but longitudinal validation across cohorts is limited (Štorkánová et al., 2021, 4991 citations). Right heart strain and pulmonary hypertension complicate prognosis in SSc-ILD. No unified model integrates clinical, imaging, and molecular predictors.
Optimizing Antifibrotic Therapy
Nintedanib slows FVC decline in SSc-ILD but lacks skin or overall SSc benefits, with high gastrointestinal adverse events (Distler et al., 2019, 1497 citations). EULAR guidelines recommend it alongside immunosuppressants, yet combination efficacy data are sparse (Kowal-Bielecka et al., 2016, 1079 citations). Patient selection via biomarkers remains unrefined.
Essential Papers
Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study
Hana Štorkánová, Sabína Oreská, Maja Špiritović et al. · 2021 · Scientific Reports · 5.0K citations
2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
F.H.J. van den Hoogen, Dinesh Khanna, Jaap Fransen et al. · 2013 · Arthritis & Rheumatism · 3.3K citations
Objective The 1980 American College of Rheumatology (ACR) classification criteria for systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present work, by a joint...
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Oliver Distler, Kristin B. Highland, Martina Gahlemann et al. · 2019 · New England Journal of Medicine · 1.5K citations
Among patients with ILD associated with systemic sclerosis, the annual rate of decline in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib was observed for other m...
Changes in causes of death in systemic sclerosis, 1972–2002
V. Steen, Thomas A. Medsger · 2007 · Annals of the Rheumatic Diseases · 1.5K citations
Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases
Thomas A. Wynn · 2007 · Journal of Clinical Investigation · 1.4K citations
Fibroproliferative diseases, including the pulmonary fibroses, systemic sclerosis, liver cirrhosis, cardiovascular disease, progressive kidney disease, and macular degeneration, are a leading cause...
Transforming growth factor–β in tissue fibrosis
Nikolaos G. Frangogiannis · 2020 · The Journal of Experimental Medicine · 1.1K citations
TGF-β is extensively implicated in the pathogenesis of fibrosis. In fibrotic lesions, spatially restricted generation of bioactive TGF-β from latent stores requires the cooperation of proteases, in...
Systemic sclerosis: a prototypic multisystem fibrotic disorder
John Varga, David Abraham · 2007 · Journal of Clinical Investigation · 1.1K citations
A unique feature of systemic sclerosis (SSc) that distinguishes it from other fibrotic disorders is that autoimmunity and vasculopathy characteristically precede fibrosis. Moreover, fibrosis in SSc...
Reading Guide
Foundational Papers
Start with van den Hoogen et al. (2013, 3271 citations) for SSc classification including lung involvement, then Varga & Abraham (2007, 1127 citations) for multisystem fibrosis pathogenesis, and Steen & Medsger (2007, 1489 citations) for mortality shifts to pulmonary causes.
Recent Advances
Study Štorkánová et al. (2021, 4991 citations) for Hsp90 biomarkers linking skin-lung fibrosis, Distler et al. (2019, 1497 citations) for nintedanib RCT, and Frangogiannis (2020, 1135 citations) for TGF-β mechanisms.
Core Methods
High-resolution CT for fibrosis patterns; FVC spirometry for progression; plasma biomarkers (Hsp90); nintedanib RCTs; classification criteria scoring (van den Hoogen et al., 2013).
How PapersFlow Helps You Research Pulmonary Fibrosis in Systemic Sclerosis
Discover & Search
Research Agent uses searchPapers('Pulmonary Fibrosis Systemic Sclerosis biomarkers') to retrieve Štorkánová et al. (2021, 4991 citations), then citationGraph reveals downstream studies on Hsp90 validation, while findSimilarPapers identifies related antifibrotic trials like Distler et al. (2019). exaSearch scans preprints for unpublished SSc-ILD cohorts.
Analyze & Verify
Analysis Agent applies readPaperContent on Distler et al. (2019) to extract FVC decline rates, then verifyResponse with CoVe cross-checks against Steen & Medsger (2007) mortality data. runPythonAnalysis performs survival curve meta-analysis via pandas on FVC datasets from multiple papers, with GRADE grading assigning high evidence to nintedanib RCTs.
Synthesize & Write
Synthesis Agent detects gaps in biomarker-driven therapy trials post-Štorkánová et al. (2021), flagging contradictions between Hsp90 skin-lung correlations. Writing Agent uses latexEditText for manuscript sections, latexSyncCitations integrates 10 SSc papers, latexCompile generates PDF, and exportMermaid visualizes TGF-β pathway diagrams from Frangogiannis (2020).
Use Cases
"Extract FVC decline rates from SSc-ILD trials and plot meta-analysis"
Research Agent → searchPapers('Nintedanib SSc ILD') → Analysis Agent → readPaperContent(Distler 2019) + runPythonAnalysis(pandas meta-analysis plot) → matplotlib survival curve output.
"Write LaTeX review on Hsp90 biomarkers in SSc pulmonary fibrosis"
Synthesis Agent → gap detection(Štorkánová 2021) → Writing Agent → latexEditText(draft) → latexSyncCitations(10 papers) → latexCompile → camera-ready PDF with citations.
"Find code for analyzing SSc lung CT fibrosis scores"
Research Agent → paperExtractUrls(Štorkánová 2021) → paperFindGithubRepo → Code Discovery → githubRepoInspect → runnable Python script for CT quantification.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ SSc-ILD papers: searchPapers → citationGraph → GRADE grading → structured report on antifibrotic efficacy. DeepScan applies 7-step analysis with CoVe checkpoints to verify Wynn (2007) fibrosis mechanisms against Distler (2019) trial data. Theorizer generates hypotheses linking Hsp90 (Štorkánová et al., 2021) to TGF-β pathways (Frangogiannis, 2020).
Frequently Asked Questions
What defines pulmonary fibrosis in systemic sclerosis?
It is SSc-associated interstitial lung disease with progressive fibrosis detected by high-resolution CT and reduced FVC, leading cause of death (Steen & Medsger, 2007, 1489 citations).
What are key treatments for SSc pulmonary fibrosis?
Nintedanib reduces FVC decline per SENSCIS trial (Distler et al., 2019, 1497 citations); EULAR recommends it with immunosuppressants (Kowal-Bielecka et al., 2016, 1079 citations).
What are seminal papers on this topic?
van den Hoogen et al. (2013, 3271 citations) for classification; Štorkánová et al. (2021, 4991 citations) for Hsp90 biomarkers; Varga & Abraham (2007, 1127 citations) for pathogenesis.
What open problems exist in SSc lung fibrosis?
Validated biomarkers for progression like Hsp90 need prospective trials; optimal nintedanib patient selection; mechanisms distinguishing SSc-ILD from idiopathic fibrosis (Wynn, 2007, 1433 citations).
Research Systemic Sclerosis and Related Diseases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pulmonary Fibrosis in Systemic Sclerosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers